Clear Cell Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR003 MIFTS: 50	Clear Cell Adenocarcinoma Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma ¹² ¹⁵ ¹⁷

Mesonephroma ¹² ⁴⁴ ⁷¹

Water-Clear Cell Adenocarcinoma ¹² ⁷¹

Adenocarcinoma, Clear Cell ⁴⁴ ⁷¹

Mesonephroid Clear Cell Carcinoma ¹²

Water-Clear Cell Carcinoma ¹²

Adenocarcinoma Clear Cell ⁵⁴

Mesonephroma, Malignant ¹²

Malignant Mesonephroma ¹²

Wolffian Duct Neoplasm ¹²

Mesonephric Tumor ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4468

MeSH ⁴⁴ D008649 D018262

NCIt ⁵⁰ C36815 C4072 C4156

SNOMED-CT ⁶⁷ 2221008 30546008 80727009

EFO ¹⁷ EFO_0000348

UMLS ⁷¹ C0025490 C0206681 C0334322 more

Sources

Summaries for Clear Cell Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to cervical clear cell adenocarcinoma and wolffian duct adenoma. An important gene associated with Clear Cell Adenocarcinoma is MUC16 (Mucin 16, Cell Surface Associated), and among its related pathways/superpathways are Gastric cancer and Human Embryonic Stem Cell Pluripotency. The drugs Lenograstim and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and lymph node, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : ⁷⁴ Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Sources

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 371)

#	Related Disease	Score	Top Affiliating Genes
1	cervical clear cell adenocarcinoma	32.6	PAX8 NAPSA
2	wolffian duct adenoma	31.6	PAX8 PAX2 KRT7 KLK3 AMACR
3	ovarian clear cell adenocarcinoma	31.6	TP53 PIK3CA NAPSA HOXA10 HNF1B ARID1A
4	urethra clear cell adenocarcinoma	31.1	SMAD4 PAX8 PAX2 KRT7 KRT20 KLK3
5	adenocarcinoma	30.9	TP53 SMAD4 SMAD3 PIK3CA NAPSA KRT7
6	bladder clear cell adenocarcinoma	30.7	TP53 PAX8 PAX2 NAPSA KRT7 KRT20
7	serous cystadenocarcinoma	30.7	TP53 PIK3CA PAX8 MUC16 ARID1A
8	cervical adenocarcinoma	30.7	TP53 KRT7 KRT20
9	urethral diverticulum	30.7	PAX8 KRT7 KLK3 AMACR
10	appendix adenocarcinoma	30.6	KRT7 KRT20
11	endodermal sinus tumor	30.6	MUC16 KRT7 KLK3 ACP3
12	ovarian serous carcinoma	30.5	TP53 PAX8 KRT7
13	clear cell adenofibroma	30.5	PIK3CA NAPSA ARID1A
14	ovarian clear cell adenofibroma	30.4	PIK3CA NAPSA
15	urethra adenocarcinoma	30.4	KLK3 AMACR
16	myoma	30.4	TP53 MUC16 HOXA10
17	cystadenocarcinoma	30.3	TP53 PIK3CA MUC16 KRT7
18	male urethral cancer	30.2	KLK3 AMACR
19	adenofibroma	30.2	TP53 NAPSA MUC16 KRT7 ARID1A
20	ovarian serous cystadenocarcinoma	30.1	TP53 PIK3CA MUC16
21	papillary adenocarcinoma	30.1	TP53 MUC16 KRT7
22	epithelial-myoepithelial carcinoma	30.1	TP53 PIK3CA KRT7
23	nephrogenic adenoma	30.0	PAX8 PAX2 KRT7 KLK3 AMACR ACP3
24	rhabdomyosarcoma	30.0	TP53 SMAD4 SMAD3 SMAD2 PIK3CA KRT7
25	adenoma	29.9	TP53 SMAD4 SMAD3 PIK3CA KRT7 KRT20
26	endosalpingiosis	29.9	PAX8 PAX2 KRT7
27	cervix carcinoma	29.9	TP53 PIK3CA PAX8 KRT7
28	carcinosarcoma	29.9	TP53 PIK3CA PAX8 KRT7
29	mucinous adenocarcinoma	29.8	TP53 MUC16 KRT7 KRT20 AMACR
30	ovary adenocarcinoma	29.7	TP53 SMAD4 PIK3CA PAX8 MUC16 KRT7
31	gallbladder adenocarcinoma	29.7	TP53 PIK3CA KRT20
32	transitional cell carcinoma	29.7	TP53 KRT7 KRT20 KLK3
33	cystitis	29.7	TP53 KRT7 KRT20
34	urinary tract obstruction	29.7	SMAD3 SMAD2 PIK3CA PAX2 KLK3
35	clear cell renal cell carcinoma	29.7	TP53 PAX8 PAX2 KRT7 ARID1A
36	ovarian brenner tumor	29.6	KRT7 KRT20
37	dysgerminoma	29.6	PTHLH KRT7 KRT20
38	papillary carcinoma	29.6	PAX8 KRT7 KRT20
39	suppression of tumorigenicity 12	29.6	TP53 SMAD4 PIK3CA KLK3 AMACR
40	small cell carcinoma	29.5	TP53 KRT7 KRT20 KLK3
41	polycystic liver disease 1 with or without kidney cysts	29.4	MUC16 KRT7 KRT20 HNF1B
42	ovarian clear cell carcinoma	29.3	TP53 PIK3CA NAPSA MUC16 KRT7 HNF1B
43	cholangiocarcinoma	29.2	TP53 SMAD4 PIK3CA KRT7 KRT20
44	glandular cystitis	29.2	TP53 KRT7 KRT20 AMACR
45	wilms tumor 1	29.1	TP53 PAX8 PAX2 KRT7 AMACR
46	intrahepatic cholangiocarcinoma	29.1	TP53 SMAD4 KRT7 KRT20 ARID1A
47	lung cancer susceptibility 3	29.0	TP53 SMAD4 PIK3CA NAPSA MUC16 KRT7
48	renal cell carcinoma, papillary, 1	29.0	TP53 PIK3CA PAX8 PAX2 KRT7 AMACR
49	endocervical adenocarcinoma	28.8	TP53 PIK3CA PAX8 PAX2 KRT7 KRT20
50	endometrial cancer	28.7	TP53 SMAD4 SMAD3 SMAD2 PIK3CA PAX8

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:

Sources

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 12)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-114	9.44	ARID1A
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-116	9.44	PIK3CA
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-157	9.44	PIK3CA
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-16	9.44	PIK3CA
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-166	9.44	PIK3CA
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-177	9.44	PIK3CA
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-190	9.44	PIK3CA SMAD2
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-2	9.44	SMAD2
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	9.44	PIK3CA
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-42	9.44	PIK3CA
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-49	9.44	PIK3CA
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-53	9.44	PIK3CA

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.17	ARID1A HOXA10 KLK3 PAX2 PAX8 PIK3CA
2	cellular	MP:0005384	10.14	ARID1A HNF1B KRT7 PAX2 PAX8 PIK3CA
3	endocrine/exocrine gland	MP:0005379	10.03	ACP3 ARID1A HNF1B HOXA10 PAX2 PAX8
4	embryo	MP:0005380	9.97	ARID1A HNF1B PAX2 PAX8 PIK3CA SMAD2
5	craniofacial	MP:0005382	9.91	ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
6	neoplasm	MP:0002006	9.76	ACP3 ARID1A PIK3CA PTHLH SMAD2 SMAD3
7	renal/urinary system	MP:0005367	9.56	HNF1B KRT7 PAX2 PAX8 PTHLH SMAD3
8	reproductive system	MP:0005389	9.36	ACP3 ARID1A HOXA10 PAX2 PAX8 PIK3CA

Sources

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Metformin

Approved

Phase 2, Phase 3

657-24-9

14219 4091

Carboplatin

Approved

Phase 3

41575-94-4

10339178 498142 38904

Rucaparib

Approved, Investigational

Phase 3

283173-50-2

9931954

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Paclitaxel poliglumex

Experimental, Investigational

Phase 3

263351-82-2

Carotenoids

Phase 3

Adjuvants, Immunologic

Phase 3

taxane

Phase 3

Immunosuppressive Agents

Phase 3

Anti-Infective Agents

Phase 3

Antimetabolites

Phase 3

Antiviral Agents

Phase 3

Hypoglycemic Agents

Phase 2, Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3

Tin Fluorides

Phase 3

Immunoglobulin G

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Immunoglobulins

Phase 2, Phase 3

Immunologic Factors

Phase 2, Phase 3

Mitogens

Phase 2, Phase 3

Immunoglobulins, Intravenous

Phase 2, Phase 3

Antibodies, Monoclonal

Phase 2, Phase 3

Antibodies

Phase 2, Phase 3

Endothelial Growth Factors

Phase 2, Phase 3

Antibiotics, Antitubercular

Phase 2, Phase 3

Anti-Bacterial Agents

Phase 2, Phase 3

Liposomal doxorubicin

Phase 2, Phase 3

31703

Vinblastine

Approved

Phase 2

865-21-4

13342 241903

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Sunitinib

Approved, Investigational

Phase 2

341031-54-7, 557795-19-4

5329102

Iodine

Approved, Investigational

Phase 1, Phase 2

7553-56-2

807

Nintedanib

Approved

Phase 2

656247-17-5

56843413

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Interventional clinical trials:

(show top 50) (show all 86)

#	Name	Status	NCT ID	Phase	Drugs
1	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
2	A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
3	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4	Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel	Recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
5	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Recruiting	NCT02502266	Phase 2, Phase 3	Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
6	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
7	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Recruiting	NCT03422198	Phase 3
8	Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy	Recruiting	NCT04575935	Phase 3	Chemotherapy
9	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
10	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
11	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
12	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02446600	Phase 3	Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
13	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
14	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Active, not recruiting	NCT00807768	Phase 3	Carboplatin;Paclitaxel
15	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
16	Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients	Not yet recruiting	NCT04227522	Phase 3	Rucaparib;Placebos
17	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer	Suspended	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18	Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study	Unknown status	NCT00226798	Phase 2	Capecitabine (Xeloda)
19	MEDI4736 Combinations in Metastatic Renal Cell Carcinoma	Unknown status	NCT02819596	Phase 2	Savolitinib;MEDI4736;Tremelimumab
20	A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	NCT00888615	Phase 2	Elesclomol Sodium;Paclitaxel
21	A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum	Completed	NCT02315430	Phase 2	Cabozantinib S-malate
22	A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma	Completed	NCT00979992	Phase 2	Sunitinib Malate
23	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
24	A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01011933	Phase 2	Selumetinib
25	Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma	Completed	NCT01824615	Phase 2	Sunitinib
26	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
27	Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	Completed	NCT01914510	Phase 2	ENMD-2076
28	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
29	A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
30	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
31	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
32	A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma	Completed	NCT00025467	Phase 2	thalidomide
33	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
34	A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
35	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
36	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
37	Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer	Recruiting	NCT02068794	Phase 1, Phase 2
38	A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)	Recruiting	NCT03405454	Phase 2	durvalumab;standard chemotherapy
39	A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies	Recruiting	NCT03297424	Phase 1, Phase 2	PLX2853
40	A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium	Recruiting	NCT02866370	Phase 2	Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
41	A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer	Recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
42	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
43	A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers	Recruiting	NCT03924245	Phase 1, Phase 2	Entinostat;Olaparib
44	Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer	Recruiting	NCT03241745	Phase 2	Nivolumab
45	A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)	Recruiting	NCT03866382	Phase 2	Cabozantinib S-malate
46	Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma	Recruiting	NCT04735861	Phase 2	Sintilimab;Bevacizumab Biosimilar IBI305
47	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
48	An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Recruiting	NCT03648489	Phase 2	Paclitaxel;TAK228
49	BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	Recruiting	NCT03355976	Phase 2	Nivolumab;Ipilimumab
50	A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	NCT02713386	Phase 1, Phase 2	Carboplatin;Paclitaxel;Ruxolitinib Phosphate

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Sources

Genetic Tests for Clear Cell Adenocarcinoma

Sources

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

⁴⁰

Cervix, Ovary, Lymph Node, Colon, Uterus, Prostate, Endothelial

Sources

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 1001)

#	Title	Authors	PMID	Year
1	Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. ⁵⁴ ⁶¹	Tsukioka M...Ishiko O	17611657	2007
2	MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. ⁵⁴ ⁶¹	Cirpan T...Sagol S	17713092	2007
3	The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. ⁶¹ ⁵⁴	Mabuchi Y...Umesaki N	16820918	2006
4	PTEN expression in clear cell adenocarcinoma of the ovary. ⁵⁴ ⁶¹	Hashiguchi Y...Mok SC	16290000	2006
5	Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate-specific antigen. ⁵⁴ ⁶¹	Kawano K...Yasuda K	11251541	2001
6	Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. ⁶¹ ⁵⁴	Tsunematsu R...Tsukamoto N	10637074	2000
7	Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. ⁶¹ ⁵⁴	Gilcrease MZ...Albores-Saavedra J	9865832	1998
8	Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. ⁶¹ ⁵⁴	Podnos YD...Manetta A	9234924	1997
9	[A case of clear cell adenocarcinoma of the female urethra]. ⁵⁴ ⁶¹	Miyai M...Ebisuno S	7645457	1995
10	Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. ⁶¹ ⁵⁴	Ebisuno S...Nagareda T	7536368	1995
11	Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. ⁵⁴ ⁶¹	Malpica A...Ayala AG	7512941	1994
12	Clear Cell Adenocarcinoma in Men: A Series of 15 Cases. ⁶¹	Grosser D...Epstein JI	32960833	2021
13	Early stage clear cell adenocarcinoma coexisting with tubular adenoma and adenoma with clear cell change in the colon. ⁶¹	Tochio T...Kushima R	33420668	2021
14	Clear cell carcinoma of the urinary bladder: a systematic review. ⁶¹	Chan EO...Teoh JY	33462714	2021
15	Diethylstilbestrol exposure during pregnancy with primary clear cell carcinoma of the cervix in an 8-year-old granddaughter: a multigenerational effect of endocrine disruptors? ⁶¹	Gaspari L...Sultan C	33147330	2021
16	Screening for cancers of the cervix and vagina for women exposed to diethylstilbestrol (DES) in utero. ⁶¹	Tournaire M...Levadou A	33310134	2020
17	Colonic clear cell adenocarcinoma with enteroblastic differentiation. ⁶¹	Shiratori Y...Ikeya T	32803644	2020
18	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. ⁶¹	Paner GP...Amin MB	33284194	2020
19	Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer. ⁶¹	Azar WJ...Bowtell DDL	32917727	2020
20	Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy. ⁶¹	O'Neill RS...Thomas D	32776490	2020
21	Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma. ⁶¹	Wang X...Hawkins SM	32843721	2020
22	Appendageal tumors and tumor-like lesions of the testis and paratestis: a 32-year experience at a single institution. ⁶¹	Al-Obaidy KI...Idrees MT	32619438	2020
23	Perineural Spread of Clear Cell Adenocarcinoma of Müllerian Origin Resulting in Neoplastic Lumbosacral Plexopathy. ⁶¹	Murthy NK...Spinner RJ	32592970	2020
24	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). ⁶¹	Ngoi NY...Tan DS	32591370	2020
25	Outcomes of surgical resection for pulmonary metastasis from ovarian cancer. ⁶¹	Kanzaki R...for Thoracic Surgery Study Group of Osaka University (TSSGO)	32703262	2020
26	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. ⁶¹	Kim J...Hewitt SM	32316112	2020
27	Three female patients with a periurethral mass: from various complaints to rare pathology. ⁶¹	Viester MD...Schotman M	32276998	2020
28	Clear cell adenocarcinoma arising from the abdominal wall after cesarean section in a patient with uterine adenomyosis. ⁶¹	Provendier A...Ferron G	32280445	2020
29	Primary Clear Cell Adenocarcinoma of the Head and Neck: A Population-Based Analysis. ⁶¹	Mukdad L...St John MA	32013719	2020
30	Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report. ⁶¹	Shields LBE...Kalebasty AR	32355644	2020
31	A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure. ⁶¹	Mathew Thomas V...Vredenburgh J	32461864	2020
32	Clear Cell Adenocarcinoma of Uterine Cervix: A Single Institution Retrospective Experience. ⁶¹	Liu Z...Liu J	33282724	2020
33	Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature. ⁶¹	Levinson A...Stieglitz E	33283136	2020
34	Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy. ⁶¹	Tesfai FM...Beltman JJ	31744889	2020
35	Fertility-preserving local excision under a hysteroscope with combined chemotherapy in a 6-year-old child with clear cell adenocarcinoma of the cervix: A case report and review of the literature. ⁶¹	Su Y...Zhang M	32000369	2020
36	Relationship between clinical and histopathological features of patients undergoing cholecystectomy. ⁶¹	Akbulut S...Sogutcu N	32550945	2020
37	Clear Cell Adenocarcinoma of the Urinary Bladder Is a Glycogen-Rich Tumor with Poorer Prognosis. ⁶¹	Zhou Z...Sun RC	31947882	2020
38	Mixed Serous and Clear Cell Adenocarcinoma of the Ovary Presenting with Symptomatic Hypercalcemia: A Case Report and Clinical Considerations. ⁶¹	Boland JL...Shahbazi SZ	32069206	2020
39	IMRT and HDR-ICBT for Locally Advanced Clear Cell Adenocarcinoma of the Cervix in Uterus Didelphys Associated With Unilateral Renal Agenesis. ⁶¹	Lei C...Wu L	32850323	2020
40	Primary vaginal clear cell adenocarcinoma accompanied by Herlyn-Werner-Wunderlich syndrome without prenatal diethylstilbestrol exposure: a case report. ⁶¹	Mei L...Chen Y	33284870	2020
41	Distal Fibular Reconstruction Using Iliac Grafting and Emslie-Vidal's Ligamentoplasty after Exeresis of Single Renal Carcinoma Metastasis. ⁶¹	Maury E...Maury P	32181039	2020
42	Molecular profiling of clear cell adenocarcinoma of the urinary tract. ⁶¹	Lin CY...Kunder CA	31372739	2019
43	Primary Clear Cell Adenocarcinoma of the Vulva: A Case Study With Mutation Analysis and Literature Review. ⁶¹	Kojima N...Kato T	31104528	2019
44	Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma. ⁶¹	Nezhat C...Nezhat F	31624455	2019
45	Germline mutation and aberrant transcripts of WWOX in a syndrome with multiple primary tumors. ⁶¹	Xu A...Lin W	31056747	2019
46	Second primary uterine malignancies after radiation therapy for cervical cancer. ⁶¹	Papatla K...Rubin S	31069490	2019
47	Prenatal diethylstilbestrol exposure and cancer risk in women. ⁶¹	Troisi R...Palmer JR	29124779	2019
48	Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience. ⁶¹	Komura N...Kimura T	30843318	2019
49	POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. ⁶¹	Lee EK...Konstantinopoulos PA	30733993	2019
50	Clear cell adenocarcinoma of the lung: a SEER analysis. ⁶¹	Komiya T...Nakanishi Y	31106129	2019

Sources

Genes for Clear Cell Adenocarcinoma

Genes related to Clear Cell Adenocarcinoma (0 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	20	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9234924 17713092
2	KLK3	Kallikrein Related Peptidase 3	Protein Coding	17.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457 (more) 11251541 7512941
3	SMAD3	SMAD Family Member 3	Protein Coding	15.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16820918
4	SMAD4	SMAD Family Member 4	Protein Coding	15.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16820918
5	ACP3	Acid Phosphatase 3	Protein Coding	15.45	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457
6	SMAD2	SMAD Family Member 2	Protein Coding	15.2	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16820918
7	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	14.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	10637074
8	KRT7	Keratin 7	Protein Coding	13.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	PAX8	Paired Box 8	Protein Coding	13.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	TP53	Tumor Protein P53	Protein Coding	13.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	HNF1B	HNF1 Homeobox B	Protein Coding	13.38	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	13.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	13.07	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	HOXA10	Homeobox A10	Protein Coding	12.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	12.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	POU6F1	POU Class 6 Homeobox 1	Protein Coding	12.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	AMACR	Alpha-Methylacyl-CoA Racemase	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	KRT20	Keratin 20	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	PAX2	Paired Box 2	Protein Coding	12.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

⁷

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	218693	7	116312458	116438439	Amplification	MET	Clear cell adenocarcinoma
2	266962	Y	174481503	174538309	Duplication	AZF1	Clear cell adenocarcinoma

Sources

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Sources

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)

#	Super pathways	Score	Top Affiliating Genes
1	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.51	TP53 SMAD4 SMAD3 SMAD2 PIK3CA ARID1A
2	Human Embryonic Stem Cell Pluripotency ⁶³ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶³	12.42	SMAD4 SMAD3 SMAD2 HNF1B
3	Mesodermal Commitment Pathway ¹ Show member pathways Endoderm Differentiation ¹	12.4	SMAD4 SMAD3 SMAD2 PTHLH HNF1B
4	VEGF Signaling ⁶⁶ Show member pathways EGFR Signaling Pathway ⁶⁶ TGF-beta Signaling Pathway ⁶⁶ VEGF Signaling Pathway ⁶⁰	12.37	TP53 SMAD4 SMAD3 SMAD2 PIK3CA
5	Cell cycle ³⁶ ¹	12.31	TP53 SMAD4 SMAD3 SMAD2
6	DNA Damage/Telomere Stress Induced Senescence ⁶⁵ Show member pathways Formation of Senescence-Associated Heterochromatin Foci (SAHF) ⁶⁵ Packaging Of Telomere Ends ⁶⁵ Signal transduction Activin A signaling regulation ²³	12.29	TP53 SMAD4 SMAD3 SMAD2
7	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.25	TP53 SMAD4 SMAD3 SMAD2 PIK3CA PAX8
8	Translation Non-genomic (rapid) action of Androgen Receptor ²³ Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²³	12.24	TP53 SMAD3 PIK3CA KLK3
9	Wnt / Hedgehog / Notch ⁴	12.17	SMAD4 SMAD3 SMAD2 PAX2
10	Colorectal Cancer Metastasis ⁶³	12.09	TP53 SMAD4 SMAD3 SMAD2
11	Human T-cell leukemia virus 1 infection ³⁶	12.06	TP53 SMAD4 SMAD3 SMAD2 PIK3CA
12	Cellular senescence (KEGG) ³⁶	12.05	TP53 SMAD3 SMAD2 PIK3CA
13	Signaling pathways regulating pluripotency of stem cells ³⁶	12	SMAD4 SMAD3 SMAD2 PIK3CA
14	TGF-beta Signaling Pathway (WikiPathways) ¹	11.96	TP53 SMAD4 SMAD3 SMAD2
15	Pathways in cancer ³⁶	11.89	TP53 SMAD4 SMAD3 SMAD2 PIK3CA PAX8
16	TGF-beta Signaling Pathways ⁶⁴	11.84	SMAD4 SMAD3 SMAD2
17	TGF-beta signaling pathway (KEGG) ³⁶	11.83	SMAD4 SMAD3 SMAD2
18	Cytokine production by Th17 cells in CF (Mouse model) ²³ Show member pathways Cytokine production by Th17 cells in CF ²³	11.82	SMAD4 SMAD3 SMAD2
19	DNA Damage Response (only ATM dependent) ¹	11.82	TP53 SMAD4 SMAD3 PIK3CA
20	Th17 Differentiation Pathway ⁶⁴ Show member pathways IL-21 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴	11.8	SMAD4 SMAD3 SMAD2
21	Androgen receptor signaling pathway ¹	11.8	SMAD4 SMAD3 KLK3
22	Validated targets of C-MYC transcriptional activation ¹	11.74	TP53 SMAD4 SMAD3
23	Regulation of nuclear SMAD2/3 signaling ¹	11.72	SMAD4 SMAD3 SMAD2
24	Loss of Function of SMAD2/3 in Cancer ⁶⁵ Show member pathways BMP Signalling Pathway ¹ Canonical and Non-Canonical TGF-B signaling ¹ Loss of Function of SMAD4 in Cancer ⁶⁵ Loss of Function of TGFBR1 in Cancer ⁶⁵ Loss of Function of TGFBR2 in Cancer ⁶⁵ SMAD2/3 MH2 Domain Mutants in Cancer ⁶⁵ SMAD2/3 Phosphorylation Motif Mutants in Cancer ⁶⁵ SMAD4 MH2 Domain Mutants in Cancer ⁶⁵ TGFBR1 KD Mutants in Cancer ⁶⁵ TGFBR1 LBD Mutants in Cancer ⁶⁵ TGFBR2 Kinase Domain Mutants in Cancer ⁶⁵ TGFBR2 MSI Frameshift Mutants in Cancer ⁶⁵	11.71	SMAD4 SMAD3 SMAD2
25	AGE-RAGE signaling pathway in diabetic complications ³⁶	11.71	SMAD4 SMAD3 SMAD2 PIK3CA
26	Development_TGF-beta receptor signaling ²³	11.68	SMAD4 SMAD3 SMAD2
27	TGF-beta receptor signaling activates SMADs ⁶⁵ Show member pathways Downregulation of TGF-beta receptor signaling ⁶⁵ Signaling by TGF-beta Receptor Complex in Cancer ⁶⁵	11.65	SMAD4 SMAD3 SMAD2
28	Transcription_P53 signaling pathway ²³	11.64	TP53 SMAD4 SMAD3 SMAD2
29	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.62	TP53 PIK3CA ARID1A
30	TGF-beta Receptor Signaling (WikiPathways) ¹	11.56	SMAD4 SMAD3 SMAD2
31	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶³ Show member pathways TOB in T-Cell Signaling ⁶³	11.49	SMAD4 SMAD3 SMAD2 PIK3CA
32	TGF-beta receptor signaling (Pathway Interaction Database) ¹	11.48	SMAD4 SMAD3 SMAD2
33	Hepatitis C and Hepatocellular Carcinoma ¹	11.48	TP53 SMAD4 SMAD3
34	Signaling by NODAL ⁶⁵ Show member pathways Antagonism of Activin by Follistatin ⁶⁵ Regulation of signaling by NODAL ⁶⁵ Signaling by Activin ⁶⁵	11.46	SMAD4 SMAD3 SMAD2
35	Integrated Cancer Pathway ¹	11.41	TP53 SMAD3 SMAD2
36	Telomere Extension by Telomerase ⁶³ Show member pathways XAV939 inhibits tankyrase, stabilizing AXIN ⁶⁵	11.16	SMAD4 SMAD3 PIK3CA
37	Extracellular vesicle-mediated signaling in recipient cells ¹	11.13	SMAD4 SMAD3 SMAD2
38	Hypothesized Pathways in Pathogenesis of Cardiovascular Disease ¹	11.01	SMAD4 SMAD3 SMAD2
39	Regulation of cytoplasmic and nuclear SMAD2/3 signaling ¹	10.71	SMAD4 SMAD3 SMAD2
40	TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition ¹	10.59	SMAD4 SMAD3 SMAD2

Sources

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	10.21	TP53 SMAD4 SMAD3 SMAD2 PTHLH POU6F1
2	transcription factor complex	GO:0005667	9.65	TP53 SMAD4 SMAD3 SMAD2 HOXA10
3	heteromeric SMAD protein complex	GO:0071144	9.33	SMAD4 SMAD3 SMAD2
4	activin responsive factor complex	GO:0032444	9.32	SMAD4 SMAD2
5	chromatin	GO:0000785	9.32	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
6	SMAD protein complex	GO:0071141	9.13	SMAD4 SMAD3 SMAD2

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 44)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of transcription, DNA-templated	GO:0006355	10.23	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
2	regulation of transcription by RNA polymerase II	GO:0006357	10.07	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
3	negative regulation of cell proliferation	GO:0008285	10.05	TP53 SMAD4 SMAD3 SMAD2 PTHLH
4	positive regulation of transcription by RNA polymerase II	GO:0045944	10.01	TP53 SMAD4 SMAD3 SMAD2 PAX8 PAX2
5	protein deubiquitination	GO:0016579	9.99	TP53 SMAD4 SMAD3 SMAD2
6	in utero embryonic development	GO:0001701	9.96	TP53 SMAD4 SMAD3 SMAD2
7	positive regulation of transcription, DNA-templated	GO:0045893	9.92	TP53 SMAD4 SMAD3 SMAD2 PAX8 PAX2
8	anatomical structure morphogenesis	GO:0009653	9.88	SMAD4 SMAD3 SMAD2 PAX8
9	transforming growth factor beta receptor signaling pathway	GO:0007179	9.87	TP53 SMAD4 SMAD3 SMAD2
10	liver development	GO:0001889	9.86	SMAD3 PIK3CA HNF1B
11	negative regulation of transforming growth factor beta receptor signaling pathway	GO:0030512	9.85	TP53 SMAD3 SMAD2
12	BMP signaling pathway	GO:0030509	9.85	SMAD4 SMAD3 SMAD2
13	SMAD protein signal transduction	GO:0060395	9.83	SMAD4 SMAD3 SMAD2
14	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.81	SMAD4 SMAD3 SMAD2
15	positive regulation of pri-miRNA transcription by RNA polymerase II	GO:1902895	9.77	TP53 SMAD4 SMAD3
16	branching involved in ureteric bud morphogenesis	GO:0001658	9.77	SMAD4 PAX8 PAX2
17	endoderm development	GO:0007492	9.75	SMAD4 SMAD3 SMAD2
18	developmental growth	GO:0048589	9.73	SMAD4 SMAD3 SMAD2
19	secondary palate development	GO:0062009	9.69	SMAD4 SMAD2
20	uterus development	GO:0060065	9.69	SMAD4 HOXA10
21	mesonephros development	GO:0001823	9.69	PAX8 PAX2
22	primary miRNA processing	GO:0031053	9.67	SMAD3 SMAD2
23	nodal signaling pathway	GO:0038092	9.67	SMAD3 SMAD2
24	pericardium development	GO:0060039	9.67	SMAD3 SMAD2
25	embryonic foregut morphogenesis	GO:0048617	9.66	SMAD3 SMAD2
26	mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0003337	9.65	PAX8 PAX2
27	regulation of metanephric nephron tubule epithelial cell differentiation	GO:0072307	9.64	PAX8 PAX2
28	metanephric epithelium development	GO:0072207	9.64	PAX8 PAX2
29	metanephric nephron tubule formation	GO:0072289	9.62	PAX8 PAX2
30	metanephric distal convoluted tubule development	GO:0072221	9.62	PAX8 PAX2
31	positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0072108	9.61	PAX8 PAX2
32	regulation of transforming growth factor beta2 production	GO:0032909	9.61	SMAD4 SMAD3
33	regulation of transforming growth factor beta receptor signaling pathway	GO:0017015	9.61	SMAD4 SMAD3 SMAD2
34	positive regulation of metanephric DCT cell differentiation	GO:2000594	9.55	PAX8 PAX2
35	negative regulation of apoptotic process involved in metanephric nephron tubule development	GO:1900218	9.54	PAX8 PAX2
36	negative regulation of apoptotic process involved in metanephric collecting duct development	GO:1900215	9.52	PAX8 PAX2
37	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	9.51	PAX8 PAX2
38	negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	GO:0072305	9.49	PAX8 PAX2
39	paraxial mesoderm morphogenesis	GO:0048340	9.48	SMAD3 SMAD2
40	pronephric field specification	GO:0039003	9.46	PAX8 PAX2
41	gastrulation	GO:0007369	9.46	TP53 SMAD4 SMAD3 SMAD2
42	SMAD protein complex assembly	GO:0007183	9.43	SMAD4 SMAD3 SMAD2
43	pronephros development	GO:0048793	9.13	PAX8 PAX2 HNF1B
44	regulation of binding	GO:0051098	8.8	SMAD4 SMAD3 SMAD2

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA binding	GO:0003677	10.16	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
2	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	9.91	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
3	sequence-specific DNA binding	GO:0043565	9.88	SMAD4 SMAD3 POU6F1 PAX8 HNF1B
4	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.88	TP53 SMAD4 SMAD3 SMAD2 PAX8 HOXA10
5	transcription regulatory region sequence-specific DNA binding	GO:0000976	9.83	TP53 SMAD4 SMAD3 PAX8 PAX2
6	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.81	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
7	DNA-binding transcription factor activity	GO:0003700	9.56	TP53 SMAD4 SMAD3 SMAD2 POU6F1 PAX8
8	R-SMAD binding	GO:0070412	9.54	SMAD4 SMAD3 SMAD2
9	I-SMAD binding	GO:0070411	9.5	SMAD4 SMAD3 SMAD2
10	co-SMAD binding	GO:0070410	9.49	SMAD3 SMAD2
11	proximal promoter sequence-specific DNA binding	GO:0000987	9.02	TP53 SMAD3 SMAD2 PAX2 HNF1B

Sources

Sources for Clear Cell Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia